GSK presented updated clinical trial data for Blenrep combined with Pomalyst and dexamethasone demonstrating prolonged progression-free survival in relapsed or refractory multiple myeloma patients. These results reinforce Blenrep's efficacy and support anticipated U.S. regulatory decisions. GSK aims to revitalize Blenrep's market potential leveraging its antibody-drug conjugate technology amid competitive oncology landscapes.